N-tert-butyl-1,3-benzodioxole-5-sulfonamide | 1222561-32-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: N-tert-butyl-1,3-benzodioxole-5-sulfonamide
• CAS: 1222561-32-1
• 化学式: C₁₁H₁₅NO₄S
• 分子量: 257.31
• InChiKey: LLMMOUQSEHFXNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  73
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-tert-butyl-1,3-benzodioxole-5-sulfonamide 、 3-氯苯甲醛 在 正丁基锂 、 水 、 氯化铵 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.5h， 以80%的产率得到N-t-butyl-6-[1-(3-chlorophenyl)-1-hydroxymethyl]-benzo[d][1,3]dioxole-5-sulfonamide
  参考文献：
  名称：

  Iodotrimethylsilane and Catalytic Iodine Promoted Cyclization for the Facile Synthesis of 3-Monoarylated Five-Membered Benzosultams

  摘要：

  3-Monoarylated five-membered benzosultams with various functional groups were prepared by simple and convenient two-step procedures. N-t-Bu-benzenesulfonamides were lithiated and reacted with substituted aromatic aldehydes to form the corresponding carbinols, which were converted to the cyclic compounds via a sequence of consecutive processes mediated by TMSCl-NaI-MeCN reagent and catalytic amount of iodine. Iodine played a crucial role in the eliminating the reductive side reaction in the cyclization processes.

  DOI：

  10.3987/com-09-11884

文献信息

• Indoline derivatives and method for using and producing the same
  申请人：ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

  公开号：US10654802B2

  公开（公告）日：2020-05-19

  The present invention relates to a compound of the formula: where n, R1 and R2 are those defined herein. The present invention also relates to use of a compound of Formula 1 in treating a clinical condition associated with fibrotic disorder.

  本发明涉及式 1 的化合物，其中 n、R1 和 R2 为本文所定义者。本发明还涉及式 1 化合物在治疗与纤维化紊乱有关的临床病症中的用途。
• INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME
  申请人：ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

  公开号：US20190135746A1

  公开（公告）日：2019-05-09

  The present invention relates to a compound of the formula: where n, R and R are those defined herein. The present invention also relates to use of a compound of Formula 1 in treating a clinical condition associated with fibrotic disorder.